News Overview

Its profit after tax (PAT) margin increased sequentially by 195 bps to 5.7%, while its EBITDA margin increased sequentially by 97 bps to 21.1%.

With the receipt of this order, the company's order book stands at Rs 1,955 crore as of date.

The price band for the IPO has been fixed at Rs 285 to Rs 300 per equity share.

Recommendation: Buy; Target price: Rs 1750

Although it climbed by almost 7% YoY to Rs 9,182.31 crore, the total revenue from operations fell short of the expected Rs 9,358 crore.

Consumer prices increased 0.8% in the June quarter, below expectations of 1.0% and the lowest increase since the third quarter of 2021, according to Australian data.

Recommendation: Buy; Target price: Rs 1650

The product is bioequivalent and therapeutically equivalent to the reference-listed medicine, Mozobil Injection, 24 mg/1.2 mL (20 mg/mL) of Genzyme Corporation.

The L&T board also gave the green light for a Rs 10,000 crore share buyback program

Analysts of IIFL Capital Services see COFO continuing on this trajectory by delivering 15%/25% USD revenue/EPS Cagr over FY23-25, driven by execution of strong deal wins and improving margins.